CLINDA-DERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINDA-DERM (CLINDA-DERM).
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
| Metabolism | Clindamycin is metabolized primarily in the liver via oxidation and conjugation. Major metabolite is N-demethylclindamycin and clindamycin sulfoxide. Enzymes: CYP3A4 plays a minor role. |
| Excretion | Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces). |
| Half-life | 2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment. |
| Protein binding | 90-95% bound primarily to albumin; also binds to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-1.0 L/kg, indicating distribution into total body water with higher concentrations in tissues such as bone and abscesses. |
| Bioavailability | Topical: limited systemic absorption (~10-15% of applied dose); oral: 90-95% bioavailable; intramuscular: 100% bioavailable. |
| Onset of Action | Topical: within 1-2 weeks of regular application for acne vulgaris; systemic (oral): 1-2 hours for peak serum concentrations. |
| Duration of Action | Topical: sustained effect with continued application; systemic: dosing interval 6-8 hours to maintain therapeutic levels. |
| Molecular Weight | 424.98 |
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment due to minimal systemic absorption. |
| Pediatric use | Pediatric patients (age 12 and older): Same as adult dosing. For children <12 years, safety and efficacy not established; use only if clearly needed. |
| Geriatric use | No specific geriatric adjustment required; use caution due to potential skin atrophy with prolonged use. |
| 1st trimester | No well-controlled studies; use only if clearly needed. Avoid systemic absorption. |
| 2nd trimester | No well-controlled studies; use only if clearly needed. |
| 3rd trimester | No well-controlled studies; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for CLINDA-DERM (CLINDA-DERM).
| Placental transfer | Minimal systemic absorption after topical application; significant placental transfer unlikely. |
| Breastfeeding | Minimal systemic absorption; unlikely to cause adverse effects. Caution if applied to breast area to avoid infant ingestion. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA boxed warning for topical clindamycin.
| Serious Effects |
Hypersensitivity to clindamycin or lincomycinHistory of antibiotic-associated colitis
| Precautions | Clostridium difficile-associated diarrhea (CDAD) reported with systemic use; rare with topical but caution advised., Avoid contact with eyes, mucous membranes., May cause skin irritation, dryness., Use caution in history of gastrointestinal disease., Prolonged use may lead to overgrowth of non-susceptible organisms. |
| Food/Dietary | No known food interactions. Topical application minimizes systemic absorption; no dietary restrictions required. |
| Clinical Pearls |
Loading safety data…
| L2 |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies; however, no adequate human studies in first trimester. Clindamycin is considered low risk but should only be used if clearly needed. |
| Fetal Monitoring | No specific fetal monitoring required. Monitor for maternal adverse effects such as pseudomembranous colitis. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available. |
| Clindamycin phosphate 1% gel (CLINDA-DERM) is a topical lincosamide antibiotic effective against Propionibacterium acnes. It is often combined with benzoyl peroxide to reduce antibiotic resistance. Apply to clean, dry skin; avoid contact with eyes, mouth, and mucous membranes. May be less effective than oral clindamycin for severe acne. Warn patients that diarrhea (including C. difficile) is possible even with topical use. |
| Patient Advice | Apply a thin layer to affected areas once or twice daily as directed. · Wash hands before and after application unless treating hands. · Avoid contact with eyes, lips, mouth, and broken skin. · Inform your doctor if you develop severe diarrhea or abdominal pain. · Do not use if you have a history of colitis or antibiotic-associated diarrhea. · May cause skin dryness or peeling; use a non-comedogenic moisturizer if needed. · Sunscreen use recommended to prevent photosensitivity (rare). · Do not apply to large areas of broken or eczematous skin. · If irritation occurs, reduce frequency or discontinue use. · Do not use with other topical products without consulting your doctor. |